



Updates on Human Melioidosis

Guest Editors:

Dr. Ian Gassiep

1. UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, RBWH Campus, Brisbane 4029, Australia
2. Department of Infectious Diseases, Mater Hospital Brisbane, South Brisbane 4101, Australia
3. Pathology Queensland, Royal Brisbane & Women's Hospital, Herston 4006, Australia

Dr. Robert Norton

1. Department of Microbiology and Pathology, Townsville Hospital, Townsville 4814, Australia
2. Faculty of Medicine, University of Queensland, Brisbane, QL, Australia

Deadline for manuscript submissions:

31 January 2025

Message from the Guest Editors

The impact of melioidosis is escalating globally. This infectious disease, which predominantly affects low- and middle-income countries, remains underdiagnosed and underreported. The effect of a delayed or incorrect diagnosis ultimately results in poor patient outcomes. Rapid and cost-effective diagnostic tests remain an essential requirement for improving patient outcomes.

As *B. pseudomallei* is intrinsically resistant to a range of antimicrobial agents, first-line therapy is limited to ceftazidime or meropenem, and access to these medications may be challenging. Furthermore, there have been limited additions to the therapeutic arsenal over time. However, recent studies into novel compounds and phage therapy are promising.

Finally, the organism in question is highly recombinant and genetically diverse. This information may be relevant to both the fields of genomic epidemiology and disease prevention in the form of vaccine development.

This Special Issue seeks to provide an update on the epidemiology, diagnosis, management, and prevention of melioidosis. We welcome the submission of both review articles and original research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)